New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
10:44 EDTGSK, AGENAgenus sell-off a 'table pounding' buying opportunity, says H.C. Wainwright
H.C. Wainwright says the sell-off in shares of Agenus (AGEN) after its partner GlaxoSmithKline (GSK) announced the Phase 3 trial evaluating the MAGE-A3 cancer vaccine in non-small cell lung cancer failed to meet both endpoints is a "table pounding" buying opportunity. The firm sees an opportunity as Agenus shifts its corporate focus towards checkpoint inhibitors. It reiterates a Buy rating on the stock with an $8 price target.
News For AGEN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTAGEN, GSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTAGEN, GSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use